Showing results (51-60 of 104) with videos related to

Sort By:
Pageof 11
AIDS (London, England)|February 3, 2021
Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U eraGiordano Madeddu, Andrea De Vito, Alessandro Cozzi-Lepri, et al.
Open Forum Infectious Diseases|January 15, 2021
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected PatientsVincenzo Malagnino, Carlotta Cerva, Antonella Cingolani, et al.
Viruses|August 10, 2021
Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort StudyMartina Spaziante, Gloria Taliani, Giulia Marchetti, et al.
The American Journal of Pathology|July 11, 2002
Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1Annunziata Gloghini, Gianluca Gaidano, Luigi M Larocca, et al.
AIDS Research and Human Retroviruses|August 31, 2002
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failureAndrea Antinori, Mauro Zaccarelli, Antonella Cingolani, et al.
Plos One|November 1, 2017
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general populationAntonella Cingolani, Alessandro Cozzi Lepri, Luciana Teofili, et al.
The Journal of Antimicrobial Chemotherapy|February 2, 2013
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)Simona Di Giambenedetto, Massimiliano Fabbiani, Manuela Colafigli, et al.
Journal of the International AIDS Society|November 15, 2014
Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational settingNicola Gianotti, Alessandro Cozzi-Lepri, Andrea Antinori, et al.
Plos One|March 4, 2014
Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohortAntonella Cingolani, Alessandro Cozzi-Lepri, Adriana Ammassari, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 11, 2018
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort StudySebastiano Leone, Milensu Shanyinde, Alessandro Cozzi Lepri, et al.
Pageof 11